Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Supporting Providers After Drug Overdose Death.

Yule AM, Levin FR.

Am J Psychiatry. 2019 Mar 1;176(3):173-178. doi: 10.1176/appi.ajp.2018.18070794. No abstract available.

PMID:
30818987
2.

Deficient Functioning of Fronto-Striatal Circuits During the Resolution of Cognitive Conflict in Cannabis-Using Youth.

Cyr M, Tau GZ, Fontaine M, Levin FR, Marsh R.

J Am Acad Child Adolesc Psychiatry. 2018 Oct 30. pii: S0890-8567(18)31910-5. doi: 10.1016/j.jaac.2018.09.436. [Epub ahead of print]

PMID:
30768406
3.

Beth Macy's Dopesick.

Williams AR, Levin FR.

Cerebrum. 2018 Nov 1;2018. pii: cer-15-18. eCollection 2018 Nov-Dec.

4.

Herbert D. Kleber.

Levin FR, Lieberman JA, Pardes H.

Neuropsychopharmacology. 2019 Apr;44(5):1007. doi: 10.1038/s41386-019-0318-7. Epub 2019 Feb 4. No abstract available.

PMID:
30718705
5.

Development of a Cascade of Care for responding to the opioid epidemic.

Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M.

Am J Drug Alcohol Abuse. 2019;45(1):1-10. doi: 10.1080/00952990.2018.1546862. Epub 2019 Jan 24.

PMID:
30675818
6.

A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.

Sullivan MA, Bisaga A, Pavlicova M, Carpenter KM, Choi CJ, Mishlen K, Levin FR, Mariani JJ, Nunes EV.

Am J Psychiatry. 2019 Feb 1;176(2):129-137. doi: 10.1176/appi.ajp.2018.17070732. Epub 2018 Oct 19.

7.

Corrigendum to "Developing an opioid use disorder treatment cascade: A review of quality measures" [Journal of Substance Abuse Treatment 91 (2018) 57-68].

Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, Remien RH, Crystal S, Friedmann PD, Levin FR, Olfson M.

J Subst Abuse Treat. 2018 Sep;92:99. doi: 10.1016/j.jsat.2018.06.015. Epub 2018 Jul 9. No abstract available.

PMID:
30032951
8.

Developing an opioid use disorder treatment cascade: A review of quality measures.

Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, Remien RH, Crystal S, Friedmann PD, Levin FR, Olfson M.

J Subst Abuse Treat. 2018 Aug;91:57-68. doi: 10.1016/j.jsat.2018.06.001. Epub 2018 Jun 2. Erratum in: J Subst Abuse Treat. 2018 Sep;92:99.

9.

How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis.

Levin FR, Choi CJ, Pavlicova M, Mariani JJ, Mahony A, Brooks DJ, Nunes EV, Grabowski J.

Drug Alcohol Depend. 2018 Jul 1;188:135-140. doi: 10.1016/j.drugalcdep.2018.03.043. Epub 2018 May 1.

10.

Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers.

Haney M, Cooper ZD, Bedi G, Herrmann E, Comer SD, Reed SC, Foltin RW, Levin FR.

Addict Biol. 2018 Apr 16. doi: 10.1111/adb.12621. [Epub ahead of print]

PMID:
29659126
11.

Transcranial Magnetic Stimulation of Medial Prefrontal and Cingulate Cortices Reduces Cocaine Self-Administration: A Pilot Study.

Martinez D, Urban N, Grassetti A, Chang D, Hu MC, Zangen A, Levin FR, Foltin R, Nunes EV.

Front Psychiatry. 2018 Mar 16;9:80. doi: 10.3389/fpsyt.2018.00080. eCollection 2018.

12.

Commentary: Providing technical assistance for the state targeted response for opioid use disorders: Time is of the essence.

Levin FR, Cates-Wessel K.

Am J Addict. 2018 Apr;27(3):158-160. doi: 10.1111/ajad.12705. Epub 2018 Mar 23. No abstract available.

13.

International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder.

Crunelle CL, van den Brink W, Moggi F, Konstenius M, Franck J, Levin FR, van de Glind G, Demetrovics Z, Coetzee C, Luderer M, Schellekens A; ICASA consensus group, Matthys F.

Eur Addict Res. 2018;24(1):43-51. doi: 10.1159/000487767. Epub 2018 Mar 6.

14.

Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder.

Brezing CA, Choi CJ, Pavlicova M, Brooks D, Mahony AL, Mariani JJ, Levin FR.

Am J Addict. 2018 Mar;27(2):101-107. doi: 10.1111/ajad.12660. Epub 2018 Feb 19.

15.

Open-label pilot study of injectable naltrexone for cannabis dependence.

Notzon DP, Kelly MA, Choi CJ, Pavlicova M, Mahony AL, Brooks DJ, Mariani JJ, Levin FR.

Am J Drug Alcohol Abuse. 2018;44(6):619-627. doi: 10.1080/00952990.2017.1423321. Epub 2018 Feb 8.

16.

Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder.

Luo SX, Wall M, Covey L, Hu MC, Scodes JM, Levin FR, Nunes EV, Winhusen T.

Am J Drug Alcohol Abuse. 2018;44(6):653-659. doi: 10.1080/00952990.2017.1416474. Epub 2018 Jan 25.

17.

A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.

Dakwar E, Nunes EV, Hart CL, Hu MC, Foltin RW, Levin FR.

Neuropharmacology. 2018 Nov;142:270-276. doi: 10.1016/j.neuropharm.2018.01.005. Epub 2018 Jan 5.

PMID:
29309770
18.

The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.

Brezing CA, Levin FR.

Neuropsychopharmacology. 2018 Jan;43(1):173-194. doi: 10.1038/npp.2017.212. Epub 2017 Sep 6. Review.

19.

A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.

Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, Levin FR.

Drug Alcohol Depend. 2017 Aug 1;177:249-257. doi: 10.1016/j.drugalcdep.2017.04.020. Epub 2017 Jun 10.

20.

Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorder.

Williams AR, Santaella-Tenorio J, Mauro CM, Levin FR, Martins SS.

Addiction. 2017 Nov;112(11):1985-1991. doi: 10.1111/add.13904. Epub 2017 Jul 17.

21.

Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs.

Lugoboni F, Levin FR, Pieri MC, Manfredini M, Zamboni L, Somaini L, Gerra G, Gruppo InterSert Collaborazione Scientifica Gics.

Psychiatry Res. 2017 Apr;250:210-216. doi: 10.1016/j.psychres.2017.01.052. Epub 2017 Jan 21.

22.

Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.

Williams AR, Barbieri V, Mishlen K, Levin FR, Nunes EV, Mariani JJ, Bisaga A.

Am J Addict. 2017 Jun;26(4):319-325. doi: 10.1111/ajad.12527. Epub 2017 Mar 22.

23.

Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?

Carpentier PJ, Levin FR.

Harv Rev Psychiatry. 2017 Mar/Apr;25(2):50-64. doi: 10.1097/HRP.0000000000000122. Review.

24.

Towards Precision Addiction Treatment: New Findings in Co-morbid Substance Use and Attention-Deficit Hyperactivity Disorders.

Luo SX, Levin FR.

Curr Psychiatry Rep. 2017 Mar;19(3):14. doi: 10.1007/s11920-017-0769-7. Review.

25.

Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.

Sullivan M, Bisaga A, Pavlicova M, Choi CJ, Mishlen K, Carpenter KM, Levin FR, Dakwar E, Mariani JJ, Nunes EV.

Am J Psychiatry. 2017 May 1;174(5):459-467. doi: 10.1176/appi.ajp.2016.16050548. Epub 2017 Jan 10.

26.

A review of a national training initiative to increase provider use of MAT to address the opioid epidemic.

Levin FR, Bisaga A, Sullivan MA, Williams AR, Cates-Wessel K.

Am J Addict. 2016 Dec;25(8):603-609. doi: 10.1111/ajad.12454. Epub 2016 Nov 2. Review.

27.

Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence.

Notzon DP, Mariani JJ, Pavlicova M, Glass A, Mahony AL, Brooks DJ, Grabowski J, Levin FR.

Am J Addict. 2016 Dec;25(8):666-672. doi: 10.1111/ajad.12467. Epub 2016 Nov 11.

28.

A Clinician's Guide to Co-occurring ADHD among Adolescent Substance Users: Comorbidity, Neurodevelopmental Risk, and Evidence-based Treatment Options.

Hogue A, Evans SW, Levin FR.

J Child Adolesc Subst Abuse. 2017;26(4):277-292. doi: 10.1080/1067828X.2017.1305930. Epub 2017 Apr 24.

29.

Maintenance of certification: How performance in practice changes improve tobacco cessation in addiction psychiatrists' practice.

Ford JH 2nd, Oliver KA, Giles M, Cates-Wessel K, Krahn D, Levin FR; MOC Addiction Psychiatry.

Am J Addict. 2017 Jan;26(1):34-41. doi: 10.1111/ajad.12480. Epub 2016 Dec 14.

30.

Childhood trauma exposure in substance use disorder patients with and without ADHD.

Konstenius M, Leifman A, van Emmerik-van Oortmerssen K, van de Glind G, Franck J, Moggi F, Ramos-Quiroga JA, Levin FR, Carpentier PJ, Skutle A, Bu ET, Kaye S, Demetrovics Z, Barta C, Auriecomb M, Fatséas M, Johnson B, Faraone SV, Allsop S, Carruthers S, Schoevers RA, Verspreet S, Dom G, Koeter MW, van den Brink W.

Addict Behav. 2017 Feb;65:118-124. doi: 10.1016/j.addbeh.2016.10.016. Epub 2016 Oct 24. No abstract available.

31.

Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial.

Dakwar E, Hart CL, Levin FR, Nunes EV, Foltin RW.

Mol Psychiatry. 2017 Jan;22(1):76-81. doi: 10.1038/mp.2016.39. Epub 2016 Apr 19.

32.

ADHD Is Highly Prevalent in Patients Seeking Treatment for Cannabis Use Disorders.

Notzon DP, Pavlicova M, Glass A, Mariani JJ, Mahony AL, Brooks DJ, Levin FR.

J Atten Disord. 2016 Mar 31. pii: 1087054716640109. [Epub ahead of print]

33.

Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients.

Mariani JJ, Malcolm RJ, Mamczur AK, Choi JC, Brady R, Nunes E, Levin FR.

Am J Drug Alcohol Abuse. 2016 May;42(3):333-40. doi: 10.3109/00952990.2015.1125493. Epub 2016 Mar 10.

34.

Persistence and Subtype Stability of ADHD Among Substance Use Disorder Treatment Seekers.

Kaye S, Ramos-Quiroga JA, van de Glind G, Levin FR, Faraone SV, Allsop S, Degenhardt L, Moggi F, Barta C, Konstenius M, Franck J, Skutle A, Bu ET, Koeter MW, Demetrovics Z, Kapitány-Fövény M, Schoevers RA, van Emmerik-van Oortmerssen K, Carpentier PJ, Dom G, Verspreet S, Crunelle CL, Young JT, Carruthers S, Cassar J, Fatséas M, Auriacombe M, Johnson B, Dunn M, Slobodin O, van den Brink W.

J Atten Disord. 2016 Feb 27. pii: 1087054716629217. [Epub ahead of print]

35.

Derived relations moderate the association between changes in the strength of commitment language and cocaine treatment response.

Carpenter KM, Amrhein PC, Bold KW, Mishlen K, Levin FR, Raby WN, Evans SM, Foltin RW, Nunes EV.

Exp Clin Psychopharmacol. 2016 Apr;24(2):77-89. doi: 10.1037/pha0000063. Epub 2016 Feb 25.

PMID:
26914460
36.

Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.

Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, Nunes EV, Bisaga A, Dakwar E, Carpenter KM, Sullivan MA, Choi JC.

Drug Alcohol Depend. 2016 Feb 1;159:53-60. doi: 10.1016/j.drugalcdep.2015.11.025. Epub 2015 Nov 27.

37.

Psychometric properties of the Barkley Deficits in Executive Functioning Scale: A Spanish-Language Version in a community sample of puerto rican adults.

Vélez-Pastrana MC, González RA, Rodríguez Cardona J, Purcell Baerga P, Alicea Rodríguez Á, Levin FR.

Psychol Assess. 2016 May;28(5):483-98. doi: 10.1037/pas0000171. Epub 2015 Aug 24.

38.

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN, Levin FR, Carpenter KM, Mariani JJ, Nunes EV.

Drug Alcohol Depend. 2015 Sep 1;154:38-45. doi: 10.1016/j.drugalcdep.2015.05.013. Epub 2015 Jul 8.

39.

Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trial.

Mooney ME, Herin DV, Specker S, Babb D, Levin FR, Grabowski J.

Drug Alcohol Depend. 2015 Aug 1;153:94-103. doi: 10.1016/j.drugalcdep.2015.05.042. Epub 2015 Jun 19.

40.

Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.

Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A, Brooks DJ, Babb D, Bai Y, Eberly LE, Nunes EV, Grabowski J.

JAMA Psychiatry. 2015 Jun;72(6):593-602. doi: 10.1001/jamapsychiatry.2015.41.

41.

Risk Factors for Borderline Personality Disorder in Treatment Seeking Patients with a Substance Use Disorder: An International Multicenter Study.

Wapp M, van de Glind G, van Emmerik-van Oortmerssen K, Dom G, Verspreet S, Carpentier PJ, Ramos-Quiroga JA, Skutle A, Bu ET, Franck J, Konstenius M, Kaye S, Demetrovics Z, Barta C, Fatséas M, Auriacombe M, Johnson B, Faraone SV, Levin FR, Allsop S, Carruthers S, Schoevers RA, Koeter MW, van den Brink W, Moggi F; IASP Research Group.

Eur Addict Res. 2015;21(4):188-94. doi: 10.1159/000371724. Epub 2015 Apr 1.

42.

Early developmental, temperamental and educational problems in 'substance use disorder' patients with and without ADHD. Does ADHD make a difference?

Skutle A, Bu ETH, Jellestad FK, van Emmerik-van Oortmerssen K, Dom G, Verspreet S, Carpentier PJ, Ramos-Quiroga JA, Franck J, Konstenius M, Kaye S, Demetrovics Z, Barta C, Fatséas M, Auriacombe M, Johnson B, Faraone SV, Levin FR, Allsop S, Carruthers S, Schoevers RA, Koeter MWJ, van den Brink W, Moggi F, Møller M, van de Glind G.

Addict Behav Rep. 2015 Mar 28;2:13-18. doi: 10.1016/j.abrep.2015.03.001. eCollection 2015 Dec.

43.

Ling et al.'s 'Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder'.

Levin FR, Mariani JJ, Bisaga A, Nunes EV.

Addiction. 2015 May;110(5):875-6. doi: 10.1111/add.12885. Epub 2015 Mar 23. No abstract available.

44.
45.

Combining seeking safety with sertraline for PTSD and alcohol use disorders: A randomized controlled trial.

Hien DA, Levin FR, Ruglass LM, López-Castro T, Papini S, Hu MC, Cohen LR, Herron A.

J Consult Clin Psychol. 2015 Apr;83(2):359-69. doi: 10.1037/a0038719. Epub 2015 Jan 26.

46.

Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.

Sullivan MA, Bisaga A, Glass A, Mishlen K, Pavlicova M, Carpenter KM, Mariani JJ, Levin FR, Nunes EV.

Drug Alcohol Depend. 2015 Feb 1;147:122-9. doi: 10.1016/j.drugalcdep.2014.11.028. Epub 2014 Dec 9.

47.
48.

Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?

Kelly MA, Pavlicova M, Glass A, Mariani JJ, Bisaga A, Sullivan MA, Nunes EV, Levin FR.

Drug Alcohol Depend. 2014 Nov 1;144:42-6. doi: 10.1016/j.drugalcdep.2014.06.040. Epub 2014 Jul 11.

49.

The self-medication hypothesis and psychostimulant treatment of cocaine dependence: an update.

Mariani JJ, Khantzian EJ, Levin FR.

Am J Addict. 2014 Mar-Apr;23(2):189-93. doi: 10.1111/j.1521-0391.2013.12086.x. Epub 2013 Sep 13. Review.

50.

Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network.

McClure EA, Sonne SC, Winhusen T, Carroll KM, Ghitza UE, McRae-Clark AL, Matthews AG, Sharma G, Van Veldhuisen P, Vandrey RG, Levin FR, Weiss RD, Lindblad R, Allen C, Mooney LJ, Haynes L, Brigham GS, Sparenborg S, Hasson AL, Gray KM.

Contemp Clin Trials. 2014 Nov;39(2):211-23. doi: 10.1016/j.cct.2014.08.011. Epub 2014 Aug 30.

Supplemental Content

Loading ...
Support Center